The prevalence of obesity is rising progressively, even among older age groups. By the year
2030–2035 over 20% of the adult US population and over 25% of the Europeans will be …

Overweight and obesity increase the risks of diabetes and cardiovascular disease (CVD).
This has been shown to be reversed with weight loss. A systematic review and meta‐analysis …

Obesity is now one of the most important global public health issues and preventable causes
of disease and mortality. In 2004, increased BMI alone was estimated to account for 2.8 …

Background The long-term effects of sibutramine treatment on the rates of cardiovascular
events and cardiovascular death among subjects at high cardiovascular risk have not been …

Background Sibutramine is a tertiary amine that has been shown to induce dose-dependent
weight loss and to enhance the effects of a low-calorie diet for up to a year. We did a …

Background Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight
and improves cardiovascular and metabolic risk factors in non-diabetic overweight or …

The development of consensus guidelines for obesity is complex. It involves recommending
both treatment interventions and interventions related to screening and prevention. With so …

Obese patients are prone to arterial hypertension, require more antihypertensive
medications, and have an increased risk of treatment-resistant arterial hypertension. Obesity-induced …

As this issue of Clinical Obesity goes to press, the world is reeling from the health, economic
and social impact of the global pandemic of COVID-19 (the disease) caused by severe …

Fatty acid metabolism in the hypothalamus has recently been shown to regulate feeding.
The selective estrogen receptor modulator tamoxifen (TMX) exerts a potent anorectic effect. …